The research is notable not only for its conclusions but for its extraordinary time horizon. Rather than a snapshot survey asking people how they slept last night, the study followed participants from young adulthood into middle age for nearly 35 years, repeatedly tracking their cannabis use across decades of their lives. In middle age, participants wore a wrist-based sleep monitor for a full week and completed sleep surveys, allowing the scientists to compare objective measures of sleep — the kind captured by sensors rather than self-assessment — with participants’ own perceptions of how well they slept. That combination of long-term exposure data and objective sleep measurement is rare in cannabis research, and it gives the findings unusual weight.

The data came from the Coronary Artery Risk Development in Young Adults, or CARDIA, Study, a long-running, community-based investigation that began in 1985 and 1986 and follows Black and white adults across the United States. Among 1,266 participants analyzed, the researchers found that greater lifetime cannabis exposure was associated with poorer objective sleep quality. People with higher cumulative cannabis use spent a lower percentage of the night actually asleep, experienced more fragmented sleep, and spent more time awake after initially falling asleep. In other words, the more cannabis people had used over their lifetimes, the more their measured sleep bore the fingerprints of disruption.

Recent cannabis users showed similar patterns. Compared with people who never used cannabis, recent users were more likely to have lower sleep efficiency, greater sleep fragmentation, and longer periods of wakefulness during the night. They were also significantly more likely to sleep longer than eight hours per night — a detail that may sound like a benefit but can itself signal poor-quality, less restorative rest. Sleep that is long but fragmented and inefficient is not the same as sleep that is deep and continuous, and the monitors used in this study were able to distinguish between the two.

The perceptual gap emerged when researchers asked participants to rate their own sleep quality. Cannabis use showed no association with whether people felt they slept well or poorly. Users and non-users reported essentially similar subjective impressions of their rest, even as the wrist-worn devices told a different story. “This was one of the most interesting findings,” said corresponding author Dr. Thanh-Huyen T. Vu, research associate professor of preventive medicine (epidemiology) at Northwestern University Feinberg School of Medicine. “The wearable device detected more nighttime disruption among participants with long-term cannabis exposure, but the participants themselves generally did not report worse sleep.”

That mismatch matters for a simple reason: people decide whether a sleep aid is working based on how they feel, not on sensor data. If cannabis subtly fragments sleep architecture without producing a conscious sense of worse rest, users may continue to believe the drug is helping them while the measurable quality of their sleep quietly deteriorates. “This study challenges the common belief that cannabis helps people sleep better,” Vu said. “Our findings suggest cannabis may actually be associated with poorer sleep quality, even if people don’t perceive those changes.”

The study was not designed to determine whether cannabis directly causes sleep problems — an important caveat, since observational research of this kind can identify associations but cannot fully rule out other explanations. People who use cannabis may differ from non-users in ways the statistical models cannot completely capture. Still, the researchers adjusted for numerous factors known to affect sleep, including age, sex, race, cigarette smoking, alcohol use, physical activity, depression, chronic health conditions, and use of other substances. Cannabis use remained associated with poorer objectively measured sleep even after those adjustments, which the authors say provides some of the strongest evidence to date that long-term recreational cannabis use and better sleep quality may not be as closely aligned as commonly believed.

“Our data do not support the belief that cannabis is helpful as a sleep aid,” said senior author Mercedes R. Carnethon, chair of the department of preventive medicine at Feinberg. “As cannabis becomes increasingly available and accepted, it’s important to better understand its long-term associations with health behaviors such as sleep.” Her point speaks to a shifting landscape: as legalization spreads and cannabis products move from dispensaries into mainstream wellness culture, marketing claims about sleep benefits have proliferated, often ahead of the scientific evidence. A study of this scale and duration offers a rare longitudinal counterweight to anecdote.

The study does have limitations that the authors themselves acknowledge. The researchers did not distinguish between modes of cannabis consumption — smoking versus consuming edibles, for example — which could matter, since different delivery methods produce different chemical exposures and timelines. And because participants were followed over several decades, patterns of cannabis use likely changed over time, reflecting shifting products, potencies, and consumption habits across the generations of legalization. The study authors said this makes consumption mode an especially important question for future research.

For people seeking better sleep in the meantime, the study’s authors point to well-established strategies that do not involve cannabis. “Keep a regular bedtime, make your bedroom cool, dark and quiet, and avoid looking at phones and other screens right before bed,” said study co-author Kristen L. Knutson, associate professor of neurology (sleep medicine) and preventive medicine (epidemiology) at Feinberg. “It can also help to establish a calming routine before sleep, such as reading, meditating or taking a shower. If sleep problems persist, or if you’re a loud snorer, talk with your health care provider to rule out an underlying sleep disorder.” Those recommendations may lack the cultural cachet of a trendy sleep aid, but unlike cannabis, they come backed by decades of sleep science — and, as this study suggests, they do not carry the risk of disrupting the very rest they are meant to improve.

Subject of Research: Long-term associations between cannabis use and objectively measured sleep quality in middle-aged adults

Article Title: Think cannabis helps you sleep better? Think again.

Article References: Think cannabis helps you sleep better? Think again.. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cannabis, sleep quality, sleep aids, wearable sleep monitors, CARDIA study, JAMA Network Open, Northwestern University, epidemiology, sleep fragmentation, sleep efficiency, marijuana, public health

The letter, authored by Maghfirotul Lathifah of PGRI Adi Buana Surabaya University in Indonesia and published on 8 October 2026, responds directly to a prospective five-year follow-up study by Partinen and colleagues that tracked changes in sleep characteristics among people with Parkinson’s disease. That study, appearing in the same journal, is among the recent efforts to move beyond cross-sectional snapshots, which capture sleep problems at a single moment, and instead document how sleep evolves over years in the same patients. The distinction matters because sleep in Parkinson’s is not static. It shifts with disease progression, with medication adjustments, and with the emergence of non-motor complications that can precede or accompany motor decline.

The technical case for this shift in perspective rests on how sleep pathology in Parkinson’s disease is organized. Sleep disturbance in these patients is not a single phenomenon but a cluster of distinct mechanisms. There is REM sleep behavior disorder, in which the normal muscle paralysis of dream sleep fails and patients physically act out their dreams, sometimes violently. There is severe fragmentation of nighttime sleep, driven by a combination of neurodegeneration in brainstem arousal and sleep-regulating circuits, nocturnal motor symptoms such as rigidity and off-period dystonia, and medication effects. There is excessive daytime sleepiness, which may reflect both nighttime disruption and direct involvement of wake-promoting systems including the orexin neurons of the hypothalamus. Each of these phenomena has a different underlying anatomy, a different time course, and, crucially, a different relationship to prognosis.

This is where the concept of functional trajectories becomes central. In Parkinson’s research, functional status refers to a patient’s capacity to perform daily activities independently, from dressing and eating to walking and managing medication. Clinical trials have historically emphasized motor scores, but what patients and families experience most acutely is the loss of functional independence. If specific sleep abnormalities reliably predict the slope of that decline, they become powerful prognostic tools, capable of identifying patients who need earlier intervention, closer monitoring, or more aggressive management of non-motor symptoms.

The evidence for such a link is already substantial in at least one domain. A 2019 study by Kim and colleagues, cited in the letter, found that REM sleep behavior disorder predicted functional dependency in early Parkinson’s disease. This finding fits within a broader literature showing that REM sleep behavior disorder is one of the strongest predictors of an aggressive disease phenotype, associated with faster progression of both motor and cognitive impairment. The mechanistic logic is compelling: the brainstem circuits that fail in REM sleep behavior disorder, particularly structures such as the sublaterodorsal nucleus and its connections, are embedded in the same networks that degenerate as the disease spreads, and their early failure may index a more widespread and rapidly advancing pathological process.

The five-year follow-up data from Partinen and colleagues add a longitudinal dimension to this picture. By measuring sleep characteristics repeatedly over five years, the study can distinguish between sleep problems that appear early and remain stable and those that emerge or worsen as the disease progresses. That temporal information is exactly what is needed to test whether sleep changes are merely consequences of advancing disease or whether they actively track and predict functional decline. A symptom that worsens in parallel with functional loss, and that can be measured objectively with tools such as polysomnography and validated questionnaires, offers clinicians a window into disease trajectory that standard motor examinations may miss.

The letter also widens the lens beyond the patient. A 2022 systematic review and meta-analysis by Sprajcer and colleagues, published in BMJ Open, documented significant sleep disturbance in caregivers of individuals with parkinsonism. This finding underscores a point that is often lost in clinical discussions: sleep pathology in Parkinson’s disease radiates outward. Nocturnal wandering in REM sleep behavior disorder can injure both patient and bed partner. Frequent nighttime awakenings mean that caregivers, who are frequently spouses of advanced age, lose sleep night after night, with documented consequences for their own health, cognitive function, and capacity to provide care. Sleep outcomes in this disease are therefore not purely individual clinical endpoints; they are markers of household-level burden.

What would it mean, in practice, to reorient clinical care around functional trajectories rather than symptom checklists? First, it would elevate sleep assessment from an optional add-on to a core component of neurological evaluation. Structured screening for REM sleep behavior disorder, objective measurement of sleep fragmentation where feasible, and systematic tracking of daytime sleepiness would become routine, not because sleep complaints deserve relief on their own, though they clearly do, but because their evolution carries prognostic information. Second, it would change how clinical trials are designed. If sleep measures predict functional dependency, they become candidate surrogate endpoints, allowing new therapies to be evaluated against outcomes that matter to patients over shorter observation periods. Third, it would sharpen the search for mechanism, since different sleep phenotypes may correspond to different patterns of neurodegeneration and thus to different therapeutic targets.

The letter’s argument also carries a caution about interpretation. Sleep symptoms and functional decline could be linked in several ways that are not mutually exclusive. Sleep disruption may be a cause of functional deterioration, through mechanisms such as impaired overnight clearance of pathological proteins, worsened daytime cognition and motor performance, and accelerated neuroinflammation. Alternatively, both sleep change and functional decline may be parallel outputs of the same underlying neurodegenerative process, making sleep a sensitive but not causal indicator. Disentangling these possibilities requires longitudinal designs with repeated measures of both sleep and function, precisely the kind of evidence the five-year follow-up study begins to provide. The letter’s contribution is to insist that this interpretive work be framed in terms of trajectories, not static symptom counts.

For a disease that affects millions worldwide and for which no therapy has yet been proven to slow its progression, the search for early, measurable, and meaningful prognostic markers is one of the most urgent tasks in neurology. The argument advanced in this letter is that sleep, long relegated to the status of a quality-of-life complaint, deserves a seat at the center of that search. If the way a patient sleeps over five years can reveal the path their disease will take, then every night of disturbed sleep is not just a symptom to be managed but a signal to be read, and reading it early may change how, and how effectively, the disease is fought.

Subject of Research: The relationship between sleep disturbances and functional trajectories in Parkinson's disease

Article Title: Beyond sleep symptoms: why functional trajectories matter in Parkinson’s disease

Article References: Lathifah, M. (2026). Beyond sleep symptoms: why functional trajectories matter in Parkinson’s disease. Journal of Clinical Sleep Medicine, 22(1), Article 190. https://doi.org/10.1007/s44470-026-00205-5

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00205-5

Keywords: Parkinson's disease, sleep disorders, REM sleep behavior disorder, functional dependency, sleep fragmentation, excessive daytime sleepiness, neurodegeneration, caregiver burden, prognosis, longitudinal study, movement disorders, Journal of Clinical Sleep Medicine

COMISA has emerged in recent years as one of the most clinically consequential phenotypes in sleep medicine. Obstructive sleep apnea, in which the upper airway repeatedly collapses during sleep and triggers intermittent drops in blood oxygen, affects an estimated 9 to 38 percent of the general population. Insomnia, characterized by difficulty falling or staying asleep with daytime consequences, is similarly widespread. What has startled researchers is how often the two overlap: roughly 30 to 50 percent of patients with sleep apnea also report chronic insomnia symptoms, and 30 to 40 percent of chronic insomnia patients show objective evidence of sleep-disordered breathing. Crucially, the combination appears to be more than the sum of its parts. Prior studies have linked COMISA to elevated risks of cardiovascular disease and incident diabetes, exceeding the risk conferred by either disorder alone, particularly when the physiological burden is measured objectively rather than by symptoms alone.

To probe the relationship between diabetes and this dual sleep disorder, investigators turned to TURKAPNE, a prospective national registry that has enrolled adults aged 18 to 80 with suspected sleep apnea from 34 centers across Türkiye since 2017. For this cross-sectional analysis, the team included 12,715 patients who underwent full-night, in-laboratory polysomnography, the gold-standard sleep test that monitors brain waves, muscle tone, eye movements, airflow, respiratory effort, and oxygen saturation. Obstructive sleep apnea was defined as an apnea-hypopnea index of at least five events per hour, while insomnia was identified through standardized questions covering difficulty initiating sleep, sleep latency of 30 minutes or longer, trouble maintaining sleep, or use of hypnotic medications. Diabetes status was based on self-reported physician diagnosis or the use of antidiabetic medications. Participants using positive airway pressure therapy or mandibular advancement devices, and those with limited life expectancy, were excluded to keep the baseline measurements clean.

The headline numbers are striking. COMISA was present in 3,275 patients, or 25.7 percent of the cohort. Diabetes was significantly more common among those with COMISA than without it, at 22.8 percent versus 15.4 percent. Flipping the perspective, roughly one in three diabetic individuals in the cohort, 33.9 percent, met criteria for COMISA, compared with 24.1 percent of non-diabetic participants. After adjusting for age, sex, body mass index, smoking status, education level, and comorbidities, diabetes remained independently associated with COMISA, with an adjusted odds ratio of 1.17. While that figure may appear modest, in a cohort of this size and in a condition as prevalent as COMISA, it translates into a substantial population-level burden, and it held firm even after accounting for obesity, the most obvious shared risk factor.

The polysomnographic comparisons within the COMISA group tell an even more compelling story about physiological severity. Diabetic patients slept shorter overall, with a median total sleep time of 353.5 minutes versus 369.0 minutes in non-diabetics, and spent more time awake after sleep onset, 50.2 minutes versus 37.8 minutes. Their arousal index, a measure of how often the brain briefly surfaces from sleep, was 18.1 events per hour compared with 14.8. Their breathing was also markedly worse: the apnea-hypopnea index reached 30.0 events per hour versus 24.0, and the oxygen desaturation index, which counts how often blood oxygen dips each hour, hit 26.0 versus 20.0. Diabetic patients also spent more time with oxygen saturation below 90 percent and reached lower nadir saturations. Sleep architecture shifted toward lighter N1 sleep with reduced rapid eye movement sleep, a pattern associated with impaired glucose metabolism in experimental studies.

Why would diabetes and COMISA feed into each other? The proposed mechanisms run in both directions. Sleep apnea drives metabolic dysfunction through intermittent hypoxia, sympathetic nervous system activation, oxidative stress, and systemic inflammation, all of which impair insulin sensitivity and pancreatic beta-cell function. Insomnia, meanwhile, is thought to act through chronic physiological hyperarousal and dysregulation of the hypothalamic-pituitary-adrenal axis, the body’s central stress system, which elevates cortisol and disrupts glucose homeostasis. When the two disorders coexist, these pathways may amplify one another: the hyperarousal of insomnia can intensify the hypoxic and inflammatory insult delivered by apneic events, deepening insulin resistance. Conversely, diabetes itself may sabotage sleep through nocturia, peripheral neuropathy, autonomic dysfunction, and altered thermoregulation, creating a self-perpetuating cycle in which metabolic derangement and sleep disruption each worsen the other.

One intriguing detail from the data supports this bidirectional reading. Among diabetic patients with COMISA, difficulty maintaining sleep was more prevalent than difficulty initiating sleep, at 50.8 percent versus 44.0 percent for trouble falling asleep. Sleep-maintenance insomnia, waking repeatedly in the middle of the night, is precisely the symptom pattern one would expect from nocturnal hypoglycemia risk, medication effects, and the urge to urinate that accompanies poorly controlled blood sugar. The diabetic COMISA patients were also more frequently female and more often obese, and they carried heavier loads of hypertension, coronary artery disease, obstructive airway disease, hypothyroidism, and psychiatric disorders. Beyond diabetes, the regression analysis identified female sex, psychiatric disease, obstructive airway disease, smoking, lower education level, and higher body mass index as independent correlates of COMISA, sketching a portrait of a phenotype that clusters with social and medical vulnerability.

The sex difference deserves particular attention. Women with sleep apnea are known to present atypically, complaining of insomnia, fatigue, and mood disturbance rather than the classic snoring and witnessed apneas that raise suspicion in men, a pattern that contributes to systematic underdiagnosis of sleep-disordered breathing in women. Hormonal changes around menopause, including declines in progesterone and estrogen, may simultaneously increase upper airway collapsibility and insomnia prevalence. Because diabetic patients with COMISA in this cohort were more often female, clinicians evaluating women with diabetes who report poor sleep should consider that both conditions may be present and that neither should be dismissed as mere stress or menopausal discomfort.

The clinical implications are straightforward, though implementing them will require a shift in routine practice. The authors argue that individuals with diabetes should be screened systematically for both insomnia symptoms and sleep-disordered breathing, rather than waiting for one or the other to declare itself. Early identification of COMISA opens the door to integrated treatment, pairing positive airway pressure therapy for the apnea with cognitive behavioral therapy for insomnia, the first-line behavioral treatment that avoids the pitfalls of long-term hypnotic medication. Whether treating COMISA aggressively improves glycemic control and reduces cardiometabolic risk in diabetic patients remains to be tested in intervention trials, but the severity gradient documented here makes the hypothesis plausible and urgent.

The study has limitations worth keeping in view. Diabetes and comorbidities were identified by self-report and medication use rather than laboratory confirmation, insomnia was assessed with symptom questions rather than full diagnostic criteria, and details on diabetes duration, glycemic control, and specific drug classes were unavailable. Because the design is cross-sectional, causality cannot be established; the data show association, not direction. The cohort was also exclusively Turkish, which may limit generalizability. Still, with 12,715 polysomnographically characterized patients, the statistical signal is hard to dismiss. If roughly a third of people with diabetes carry a combined sleep disorder that worsens both their nights and their metabolism, then the sleep clinic and the diabetes clinic may need to stop operating as separate worlds, and the humble question about sleep quality may become one of the cheapest diagnostic tools in metabolic medicine.

Subject of Research: The association between diabetes mellitus and comorbid insomnia and obstructive sleep apnea (COMISA)

Article Title: Diabetes mellitus is associated with increased prevalence and severity of COMISA: evidence from the nationwide TURKAPNE cohort

Article References: Gürkan, C. G., Pihtili, A., Kiyan, E., Tasbakan, M. S., Basoglu, Ö. K., Arbatli, S., Aydin, S., Cilli, A., Dursunoglu, N., Baran, B., Peker, Y., Turkapne Study Group, Ursavaş, A., Annakkaya, A. N., Aksakal, A., Balcı, A., Utkusavaş, A., Ugurlu, A. Ö., Elmalı, A. D., … Zeren Uçar, Z. (2026). Diabetes mellitus is associated with increased prevalence and severity of COMISA: evidence from the nationwide TURKAPNE cohort. Journal of Clinical Sleep Medicine, 22(1), Article 103. https://doi.org/10.1007/s44470-026-00109-4

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00109-4

Keywords: diabetes mellitus, COMISA, insomnia, obstructive sleep apnea, polysomnography, sleep fragmentation, TURKAPNE cohort, insulin resistance, sleep-disordered breathing, metabolic dysfunction, intermittent hypoxia, sleep medicine

The study, published in the Journal of Clinical Sleep Medicine, set out to answer a deceptively simple question: does a questionnaire validated largely in high-income, Western settings measure sleep the same way among young, predominantly low-income women in urban South Africa? The answer, according to the research team led by Stephanie Alcock of the University of the Witwatersrand, is a qualified no. When the researchers subjected the data to confirmatory factor analysis, the statistical technique used to test whether a set of questionnaire items hangs together as a single underlying construct, the original one-factor model of the PSQI performed poorly. The model produced a Comparative Fit Index of just 0.65 and a Tucker-Lewis Index of 0.48, both far below the accepted threshold of 0.90, with a Root Mean Square Error of Approximation of 0.13, more than double the 0.06 cutoff that signals good fit.

In plain terms, the numbers mean that treating the seven components of the PSQI, which cover subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction, as reflections of one single latent trait called sleep quality does not describe how these women actually experience their sleep. When the researchers instead tested multidimensional alternatives, the picture changed dramatically. A two-factor model, which grouped sleep duration and habitual sleep efficiency under one latent factor and the remaining components under another, achieved a Comparative Fit Index of 0.94 and an RMSEA of 0.05, comfortably within the range considered good. A three-factor model performed nearly as well, but with a caveat: the correlation between its sleep latency and sleep quality factors exceeded one, a statistical red flag indicating those two constructs could not be reliably distinguished in this sample.

The internal consistency figures tell a similar story of an instrument under strain. Cronbach’s alpha and McDonald’s omega, the two standard measures of how coherently a scale’s items hang together, both came in at 0.57, well below the conventional benchmark of 0.70, though some methodologists accept values of 0.50 or higher. Item-total correlations ranged from 0.33 for the sleep medication component to 0.65 for sleep duration, and the sleep medication item showed the weakest relationship with the rest of the scale at just 0.15. The researchers note that removing the medication component barely changed the overall reliability, a pattern likely rooted in context: prescription sleep aids are often unavailable or unaffordable in this setting, and many women may not view poor sleep as a condition that warrants treatment at all.

Perhaps the most striking finding is not statistical but epidemiological. On average, the women in the study spent 9.5 hours in bed and reported sleeping 7.8 hours, figures that would suggest ample sleep opportunity by almost any standard. Yet 42.6 percent of the sample scored above the PSQI’s global cutoff of 5, classifying them as poor sleepers, a prevalence that exceeds estimates from Germany but sits in line with figures from Spain and South Korea. The median bedtime was 22:00 and the median wake time 07:00, but median sleep onset latency stretched to 20 minutes and fragmentation scores pointed to frequent nocturnal disruptions. The data paint a picture in which the problem is not too little time for sleep but too little continuous sleep, a continuity crisis rather than an opportunity shortage.

This distinction matters because it reframes what poor sleep means in this population. The researchers found that longer time in bed was moderately associated with longer sleep duration, meaning that extra opportunity did translate into more sleep, but greater fragmentation was linked to shorter sleep duration. In other words, women were getting enough hours in bed, yet nocturnal interruptions, whether from noise, crowding, caregiving, or hypervigilance related to safety concerns, were eroding the restorative value of that time. The authors suggest that in urban South African townships, environmental and psychosocial stressors such as material deprivation, overcrowded households, caregiving demands, and fear-driven alertness may disrupt sleep onset, reduce efficiency, and normalize fatigue, causing women to experience disturbed sleep, daytime tiredness, and negative evaluations of their sleep as one blended phenomenon rather than separate problems.

The sociodemographic correlates add another layer of intrigue. Poor sleep quality was associated with higher household socioeconomic status measured by an asset score, higher educational attainment, and single relationship status, while age made no difference in this young cohort. The authors caution that these associations, drawn from a global cutoff score that the study itself undermines, should be interpreted carefully. Still, they speculate that educational and employment pressures, stressors accompanying low socioeconomic conditions, and reduced social support among single women may combine to shape sleep in ways that defy simple assumptions about poverty and rest. The finding that higher asset scores tracked with worse sleep is counterintuitive and underscores how context-specific sleep research must be.

The implications for measurement science are considerable. The PSQI’s factor structure has been contested for years, with studies reporting one-, two-, and three-factor solutions across populations as varied as Canadian adults, Sri Lankan patients, Portuguese older adults, Iranian students, Peruvian pregnant women, and New Zealand female workers during COVID-19 lockdowns. Even within a single multinational student study, the factor structure shifted between countries. The new South African results reinforce a growing consensus that sleep quality is not a universal, monolithic construct but a context-sensitive one, and that exporting a scoring scheme developed in Pittsburgh to a township in Johannesburg without local validation risks misclassification and misinterpretation. The authors recommend the two-factor model for this population because it is more parsimonious, fits slightly better, and avoids the discriminant validity problems that plagued the three-factor alternative.

Clinically, the message is that screening and intervention should target specific PSQI components, particularly nocturnal disruptions and the environmental factors that drive them, rather than relying on a global score that conflates distinct experiences. For young South African women, the authors argue, interventions may need to address stress-related sleep disturbance, environmental noise and crowding, and perceived sleep quality rather than simply exhorting people to spend more hours in bed. The study also positions sleep as a social determinant of health, shaped by safety, housing conditions, caregiving burdens, and financial stress, and calls for sleep health to be integrated into community health, women’s health, and public policy initiatives.

The researchers are candid about the limitations of their work. The cross-sectional design cannot capture how sleep patterns change over time, the sample of young urban women limits generalizability to men, older adults, and rural populations, and self-report measures carry the risk of reporting bias and misinterpreted items. Because no qualitative interviews accompanied the survey, the team cannot say how respondents actually understood phrases like sleep quality, and the data violated assumptions of multivariate normality, which may affect some parameter estimates. Future research, they write, should test whether the PSQI measures sleep equivalently across different groups within South Africa, deploy longitudinal designs to untangle the relationships between sleep domains and mental health, caregiving burden, and socioeconomic stress, and use qualitative methods to learn how women in Soweto define good sleep on their own terms. Until then, the study stands as a warning to global health researchers: a questionnaire is only as good as the evidence that it means the same thing everywhere it is used.

Subject of Research: Psychometric validation of the Pittsburgh Sleep Quality Index among young South African women

Article Title: Psychometric evaluation of the Pittsburgh Sleep Quality Index among South African women participating in the Bukhali trial: Healthy Life Trajectories Initiative

Article References: Psychometric evaluation of the Pittsburgh Sleep Quality Index among South African women participating in the Bukhali trial: Healthy Life Trajectories Initiative. (n.d.). https://doi.org/10.1007/s44470-026-00146-z

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00146-z

Keywords: Pittsburgh Sleep Quality Index, sleep quality, psychometrics, confirmatory factor analysis, South Africa, Soweto, women's health, sleep fragmentation, Bukhali trial, Healthy Life Trajectories Initiative, public health, measurement invariance

Scientists call this process sleep homeostasis, and it is one of the two great forces that govern when and how deeply we sleep, the other being the circadian clock. The longer we stay awake, the stronger the pressure for sleep becomes, and the classic fingerprint of that pressure is slow wave activity, the high-amplitude, low-frequency electrical waves that dominate deep non-REM sleep. In a healthy sleeper, slow wave activity is ferocious in the first NREM episode of the night and then decays steadily across successive sleep cycles, like a battery discharging as it refills. By morning, the pressure is gone. According to the influential synaptic homeostasis hypothesis, this overnight decline is not merely a byproduct of sleep but its central purpose: synapses strengthened by the day’s experience are progressively downscaled, restoring energy balance, consolidating memories, and preparing the cortex to learn again.

Lead author Rama Maganti of the University of Wisconsin School of Medicine and Public Health and colleagues asked a deceptively simple question: does this decay still work properly in people with obstructive sleep apnea, and does it get worse as the disease gets more severe? To find out, they mined polysomnography records from 945 participants in the Wisconsin Sleep Cohort, each contributing their first sleep study, collected between 1988 and 2015. Participants were divided into four groups by apnea-hypopnea index: no apnea (430 people), mild (267), moderate (120), and severe (128). Rather than relying on a single crude measure, the team quantified sleep homeostasis three independent ways: the decay of normalized slow wave activity across the night’s NREM episodes, the change in the slope of individual slow waves from the first to the last hour of sleep, and the brain’s ability to compensate with extra slow wave activity after episodes of wakefulness.

The technical execution matters here. The researchers extracted delta-band power, between 0.5 and 4 hertz, from frontal and central EEG electrodes in every 6-second epoch of N2 and N3 sleep, then normalized it against power in the theta, alpha, beta, and sigma bands to strip out individual differences in overall signal. Slow wave slopes were computed automatically by detecting zero-crossings on the filtered signal, isolating the descending segments of negative half-waves, and dividing amplitude by duration. It is a level of granularity that earlier apnea studies, which mostly tracked absolute delta power alone, never attempted. The result is the most systematic portrait to date of how sleep pressure regulation behaves across the full spectrum of sleep-disordered breathing.

The headline finding is stark. In people without apnea, and in those with mild or moderate disease, slow wave activity fell significantly between the first and fourth NREM episode of the night. In the severe apnea group, that decline vanished. The flattening of the decay curve tracked the apnea-hypopnea index across the whole cohort: the higher the AHI, the flatter the discharge of sleep pressure. Slow wave slopes told the same story. In every group except severe apnea, the slope of individual slow waves dropped significantly from the first to the last hour of NREM sleep, the expected signature of synaptic renormalization. In severe disease, the slopes barely budged, as if the brain never got the signal that its cleanup work was done. Notably, average slow wave activity itself was identical across groups, which means the pathology hides not in how much slow wave activity a person shows, but in how it moves through the night.

Fragmentation emerged as the likely culprit. Wake after sleep onset, the minutes of intrusive wakefulness scattered through the night, was strongly associated with flatter decay, and the relationship was steepest in the severe group. The study also uncovered a striking sex difference: for any given level of slow wave decay, men showed higher apnea indices than women, hinting that males may be more vulnerable to the homeostatic consequences of each respiratory event. The authors suggest that the repeated arousals triggered by airway collapse, sometimes dozens of times per hour, prevent the continuous stretches of deep sleep that the homeostatic process needs to run its course, leaving sleep pressure only partially discharged by morning.

Perhaps the most surprising chapter of the study concerns what happens outside the airway. In multivariable models adjusting for age, sex, and body mass index, several clinical factors independently predicted impaired sleep homeostasis. Diabetes was associated with flatter slow wave slopes. So were antidepressant medications, anti-anxiety drugs, antihypertensives, sedatives, and heavy caffeine intake of more than four beverages a day. When the team dissected antidepressant classes, tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors showed the strongest and most persistent associations with disrupted slow wave decay, even after covariate adjustment, while SSRIs, bupropion, and benzodiazepines did not reach significance. On the protective side, the percentage of N3 deep sleep showed a robust graded relationship with healthier homeostatic dynamics: participants with more than 12 percent N3 sleep had dramatically steeper slow wave slopes than those with almost none. Sleep homeostasis, in other words, is not simply a casualty of apnea severity but a system shaped by metabolism, pharmacology, and sleep architecture all at once.

Why should a flattened decay curve matter for health? The authors point to a growing body of evidence linking disrupted slow wave dynamics to the worst outcomes of sleep apnea. Sleep homeostasis is thought to be essential for synaptic downscaling, memory consolidation, and neuroplasticity, and disturbances in slow wave activity have been tied to deficits in attention, executive function, and working memory in apnea patients. Reduced slow wave activity and fragmented non-REM sleep are also associated with impaired glymphatic clearance of beta-amyloid, the protein that accumulates in Alzheimer’s disease, and one prior study found that amyloid levels fell and slow wave activity rose after treatment with CPAP. More ominously, a recent longitudinal study showed that a disrupted overnight dissipation of delta activity predicts all-cause mortality, and loss of slow wave decay has been documented in people who died of sudden unexpected death in epilepsy. Flattened sleep pressure dynamics may thus be a mechanistic bridge between a collapsing airway and the cardiovascular, cognitive, and mortal consequences that follow.

The study has honest limitations. It is observational, drawn from a single predominantly white cohort of middle-aged adults, so causation and generalizability remain open questions. Medication use was self-reported, standard EEG leads cannot reveal regional slow wave changes that high-density arrays might capture, and the researchers did not compare homeostatic measures before and after CPAP initiation, leaving the reversibility of the damage untested. Still, the implications are provocative. If severe apnea leaves the brain unable to discharge sleep pressure, patients may experience nonrestorative sleep even when they spend enough hours in bed, and treatments aimed solely at eliminating breathing pauses may not fully restore the underlying regulatory process. The authors argue that future trials should test whether CPAP reverses these impairments, and whether therapies should be designed to correct sleep homeostasis itself, not just the airway. For the hundreds of millions of people worldwide who stop breathing in their sleep, the deepest cost of the disease may be a brain that wakes each morning still owing the debt of the night before.

Subject of Research: Impairment of sleep homeostasis and slow wave activity dynamics across obstructive sleep apnea severity

Article Title: Sleep homeostasis impairment across obstructive sleep apnea severity: findings from a population-based cohort study

Article References: Sleep homeostasis impairment across obstructive sleep apnea severity: findings from a population-based cohort study. (n.d.). https://doi.org/10.1007/s44470-026-00131-6

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00131-6

Keywords: obstructive sleep apnea, sleep homeostasis, slow wave activity, polysomnography, NREM sleep, apnea-hypopnea index, sleep fragmentation, synaptic downscaling, antidepressants, deep sleep, Wisconsin Sleep Cohort, cognitive decline

The distinction matters because the two conditions demand different treatments. True insomnia is a disorder of hyperarousal, characterized by difficulty falling or staying asleep despite adequate opportunity, and it responds best to cognitive behavioral therapy for insomnia, or CBT-I, and, in some cases, carefully selected hypnotic medications. Obstructive sleep apnea, by contrast, is a mechanical and physiological problem: the upper airway collapses during sleep, oxygen levels dip, and the brain jolts the body awake just enough to reopen the airway. Its first-line treatment is positive airway pressure therapy. If a clinician mistakes apnea-driven fragmentation for insomnia and prescribes a sedative-hypnotic, the underlying breathing disorder may worsen, since hypnotics can suppress the arousal responses and upper-airway muscle tone that protect a vulnerable airway during sleep.

The letter responds directly to a recent analysis of the TURKAPNE cohort, a nationwide Turkish sleep study led by Gürkan and colleagues, which reported that diabetes mellitus is associated with increased prevalence and severity of COMISA. That finding, published in the same journal, seemed to confirm what many clinicians suspected: diabetes and the double burden of insomnia plus apnea travel together. But Xu and colleagues raise a methodological objection that cuts to the heart of how COMISA is diagnosed. Standard insomnia questionnaires, such as the Insomnia Severity Index, ask about difficulty falling asleep, frequent awakenings, and unrefreshing sleep. A patient with severe, untreated sleep apnea will answer yes to nearly all of those questions, not because their brain has forgotten how to sleep, but because their airway keeps waking them up.

This perceptual blind spot is one of the most counterintuitive findings in modern sleep science. Most people with obstructive sleep apnea do not remember the dozens or hundreds of brief arousals that fragment their night. Each arousal lasts only a few seconds, just long enough to restore airflow, and the sleeper typically falls back asleep without forming any memory of the event. What they remember is the consequence: a morning feeling of unrefreshing sleep, daytime fatigue, and the impression that they are an insomniac. When such a patient fills out an insomnia questionnaire, the answers faithfully report the symptom but misattribute the cause. In a population with high rates of obesity and apnea, such as people with type 2 diabetes, that misattribution can inflate the apparent prevalence of true insomnia comorbidity considerably.

The technical solution the letter points toward is objective sleep measurement. Polysomnography, the gold-standard sleep study, records brain waves, eye movements, muscle tone, airflow, respiratory effort, and blood oxygen saturation across a full night. It can quantify the apnea-hypopnea index, the number of breathing interruptions per hour of sleep, and it can reveal whether reported insomnia complaints correlate with objective sleep fragmentation from respiratory events. Studies of Asian patients with comorbid insomnia and sleep apnea, such as the 2025 analysis by Hoc and Lee published in Scientific Reports, have used polysomnographic characteristics to begin separating phenotypes: patients whose insomnia complaints track with respiratory-event-related arousals versus those with genuine difficulty initiating or maintaining sleep independent of breathing disturbances.

The stakes extend well beyond diagnostic bookkeeping. Large epidemiological studies have linked both sleep-disordered breathing and insomnia to cardiometabolic outcomes. The Hispanic Community Health Study/Study of Latinos, analyzed by Li and colleagues in the American Journal of Respiratory and Critical Care Medicine in 2021, found associations between sleep-disordered breathing, insomnia, and incident hypertension and diabetes. If apnea contributes to the development and worsening of diabetes through intermittent hypoxia, sympathetic activation, and impaired glucose metabolism, then misclassifying apnea as insomnia in diabetic patients does more than delay proper treatment; it obscures a potentially modifiable driver of the metabolic disease itself. Treating the apnea could, in principle, improve both sleep and glycemic control, whereas treating a phantom insomnia cannot.

The pharmacological dimension adds further urgency. A 2024 systematic review and meta-analysis by Messineo, Sands, and Labarca in the American Journal of Respiratory and Critical Care Medicine examined how hypnotic medications affect obstructive sleep apnea severity and endotypes. The evidence suggests that the effects of hypnotics on apnea are not uniform: some agents may worsen the disorder by prolonging apneas or blunting arousals, while the impact varies with the patient’s specific apnea endotype, meaning the anatomical and physiological pattern that produces their airway collapse. Prescribing a hypnotic to a diabetic patient whose insomnia symptoms are actually driven by unrecognized apnea therefore carries a real risk of aggravating the very condition that is destroying their sleep, potentially deepening both the sleep fragmentation and the metabolic consequences.

Xu and colleagues propose that studies examining COMISA in diabetes should incorporate objective respiratory monitoring before concluding that insomnia is genuinely comorbid. At minimum, they argue, the diagnostic pathway for a diabetic patient reporting chronic insomnia should include screening for sleep apnea, whether through validated questionnaires such as the STOP-BANG, home sleep apnea testing, or full polysomnography in complex cases. Only after excluding or adequately treating significant sleep-disordered breathing can a clinician confidently diagnose a true insomnia comorbidity and initiate CBT-I or hypnotic therapy on solid ground. This sequencing, they suggest, would sharpen both research definitions and everyday clinical practice, replacing a symptom-based label with a mechanism-based diagnosis.

The letter, which was received on 3 July 2026, accepted on 9 July, and published on 12 August 2026 as article 138 in volume 22 of the journal, was supported by the Gansu Provincial Natural Science Foundation under grant number 25JRRA266. The authors, who work across the departments of nephrology and diabetes, geriatrics, and rehabilitation medicine at Gansu Provincial Hospital of Traditional Chinese Medicine in Lanzhou, declare no competing interests. Their argument is deliberately modest in form but consequential in scope: it does not overturn the TURKAPNE finding, but it reframes it, asking whether the excess COMISA observed in diabetes reflects a true double sleep disorder or an apnea epidemic wearing an insomnia mask.

For the rapidly growing global population of people living with diabetes, the practical message is clear. Chronic insomnia complaints in this group should trigger a search for breathing-related sleep disruption before a diagnosis of comorbid insomnia is accepted and sedatives are prescribed. The tools to make that distinction already exist, from low-cost home sleep testing to full laboratory polysomnography, and the treatments for each condition are fundamentally different. As sleep researchers continue to refine the phenotypes of COMISA, the letter by Xu, Liu, and Liu serves as a reminder that in medicine, as in sleep itself, what appears on the surface is not always what is happening underneath. Getting the diagnosis right may be the first step toward a night of genuinely restorative sleep, and perhaps toward better metabolic health as well.

Subject of Research: Distinguishing true insomnia comorbidity from obstructive sleep apnea-related sleep disruption in patients with diabetes

Article Title: Clarifying COMISA in diabetes: distinguishing true insomnia comorbidity from OSA-related sleep disruption

Article References: Xu, S., Liu, X., & Liu, C. (2026). Clarifying COMISA in diabetes: distinguishing true insomnia comorbidity from OSA-related sleep disruption. Journal of Clinical Sleep Medicine, 22(1), Article 138. https://doi.org/10.1007/s44470-026-00154-z

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00154-z

Keywords: COMISA, insomnia, obstructive sleep apnea, diabetes, sleep medicine, polysomnography, CBT-I, hypnotics, TURKAPNE cohort, sleep fragmentation, type 2 diabetes, sleep-disordered breathing

The dispute began with a paper from the TURKAPNE Study Group, led by Canan Gündüz Gürkan of Süreyyapaşa Chest Diseases Research and Training Hospital in Istanbul and Yüksel Peker, a pulmonary medicine specialist whose affiliations span Koç University in Istanbul, the University of Gothenburg, Lund University, and the University of Pittsburgh. Drawing on a nationwide Turkish cohort of adults evaluated for sleep-disordered breathing, the group reported that diabetes mellitus was associated with both an increased prevalence and an increased severity of a condition known by the acronym COMISA: co-morbid insomnia and sleep apnea. The finding landed with force because COMISA sits at the intersection of two of the most common chronic sleep disorders, and because patients who carry both conditions simultaneously are known to fare worse than those with either alone.

COMISA is not a niche concern. Epidemiological surveys across multiple countries suggest that a substantial fraction of patients presenting at sleep clinics with obstructive sleep apnea also report chronic insomnia symptoms, and conversely that many insomnia patients show objective evidence of upper airway obstruction during sleep. The clinical consequences of this overlap are well documented in the review literature: people with COMISA tend to report greater daytime sleepiness, more fatigue, worse quality of life, higher rates of depression and anxiety, and greater healthcare utilization than patients with a single disorder. Treatment is also trickier, because continuous positive airway pressure, the standard therapy for sleep apnea, can be poorly tolerated by patients whose insomnia makes it difficult to sleep while wearing a mask, and hypnotic medications used for insomnia can suppress arousal responses that protect apnea patients from prolonged airway collapse.

Into this landscape stepped Xu, Liu, and Liu, whose letter to the journal bore a title that framed the entire controversy: Clarifying COMISA in diabetes: distinguishing true insomnia comorbidity from OSA-related sleep disruption. Their argument, as the title suggests, was methodological and conceptual. They contended that the TURKAPNE analysis may have conflated two fundamentally different phenomena. On one side stands genuine insomnia disorder, a condition defined by persistent difficulty initiating or maintaining sleep despite adequate opportunity, accompanied by daytime impairment, and rooted in the hyperarousal mechanisms that modern insomnia research has mapped with increasing precision. On the other side stands something quite different: the fragmented, unrefreshing sleep that results when the upper airway repeatedly collapses during the night, triggering micro-awakenings that patients may perceive as insomnia.

This distinction matters because the two conditions demand different treatments and carry different prognoses. A patient whose sleep complaints are driven entirely by untreated apnea may find their insomnia-like symptoms dissolve once positive airway pressure therapy stabilizes their breathing. A patient with true co-morbid insomnia, by contrast, will typically continue to struggle with sleep even after their apnea is controlled, and will need cognitive behavioral therapy for insomnia or pharmacological treatment in addition to their breathing therapy. If researchers label apnea-related sleep fragmentation as insomnia, they inflate the apparent prevalence of COMISA, overestimate its burden in populations such as people with diabetes, and risk sending clinicians down the wrong therapeutic path.

The TURKAPNE investigators responded in a reply published on 13 August 2026, and their response defends the clinical reality of the association they reported. Peker and Gürkan, writing on behalf of the TURKAPNE Study Group, stand by the central claim of their original paper: that in their nationwide cohort, diabetes mellitus was associated with increased prevalence and severity of COMISA. The reply, published as a letter in volume 22 of the Journal of Clinical Sleep Medicine, represents the group’s formal answer to the critique, and it underscores how seriously the original authors take the challenge to their interpretation. The exchange is compact, but the stakes it illuminates are anything but.

Why would diabetes be expected to sit at the center of this storm in the first place? The physiological connections between type 2 diabetes and disordered sleep run in both directions. Obesity, the dominant risk factor for obstructive sleep apnea, is also the dominant driver of insulin resistance, so the two conditions travel together at the population level. But the links go deeper than shared adiposity. Intermittent hypoxia and sleep fragmentation from apnea activate sympathetic nervous system outflow and stress hormone release, worsen glucose tolerance, and promote insulin resistance, creating a plausible causal pathway from breathing disorder to metabolic disease. Conversely, diabetic autonomic neuropathy can destabilize the neural control of upper airway muscles and breathing rhythm, and diabetes-related nocturia and peripheral neuropathy can fragment sleep independently of any breathing problem. Insomnia, for its part, has been repeatedly linked to impaired glucose metabolism in large cohort studies, with chronic short sleep and poor sleep quality both associated with elevated diabetes risk.

This dense web of interconnection is precisely what makes the conceptual question raised by the letter writers so difficult and so important. In a patient with diabetes, poor sleep could reflect apnea-driven fragmentation, true insomnia with its hyperarousal physiology, painful neuropathy, nocturia from poor glycemic control, depression, medications, or some tangled combination of all of these. Disentangling those threads requires careful phenotyping: polysomnography to quantify apnea severity objectively, validated insomnia instruments that probe the subjective experience of sleep and its daytime consequences, and enough clinical detail to separate apnea-related awakenings from the difficulty falling asleep and staying asleep that characterizes insomnia disorder. Large registries and cohorts such as TURKAPNE, which has previously published cross-sectional analyses of more than twelve thousand adults with moderate-to-severe obstructive sleep apnea, offer the statistical power to detect associations, but their ability to resolve fine diagnostic distinctions depends entirely on the instruments used and the definitions applied.

The broader field has been converging on a more nuanced view of COMISA in recent years. Reviews of the co-morbid insomnia and sleep apnea literature, including influential work by Sweetman and colleagues, have emphasized that the overlap is real, that it is more common than chance would predict, and that it carries additive clinical burden. At the same time, researchers have acknowledged that the boundary between the two disorders is porous, that subjective insomnia symptoms can be produced or amplified by objective sleep disruption, and that the field still lacks a universally accepted algorithm for deciding when the two conditions are genuinely co-present. Some investigators have proposed sequential treatment trials, using the response to apnea therapy as a diagnostic probe: if insomnia symptoms persist after the breathing disorder is adequately treated, that persistence itself becomes evidence for true co-morbidity. Others advocate for parallel treatment pathways that address both conditions from the outset, arguing that waiting for diagnostic clarity delays relief for patients who are suffering.

What the exchange in the Journal of Clinical Sleep Medicine ultimately demonstrates is that a single word, comorbidity, can carry enormous weight. If the TURKAPNE finding survives the methodological scrutiny, it suggests that diabetes should be treated as a red flag for combined sleep pathology, prompting clinicians who evaluate diabetic patients with sleep complaints to look for both disorders rather than stopping at the first diagnosis. If the critics are right that part of the observed association reflects apnea-related sleep disruption masquerading as insomnia, then the clinical message shifts: the priority is aggressive detection and treatment of sleep apnea in diabetic patients, with insomnia reassessed only after breathing is stabilized. Either way, the practical takeaway for patients is the same. People with diabetes who struggle with sleep should not accept fragmented nights as an inevitable feature of their disease, because the causes are identifiable, the diagnostic tools exist, and effective treatments are available for both conditions. The scientific argument over definitions will continue in the letters pages, but its resolution will shape real decisions in sleep clinics, and for the growing global population living with diabetes, those decisions could determine whether restorative sleep remains out of reach or finally comes within grasp.

Subject of Research: Co-morbid insomnia and sleep apnea (COMISA) in patients with diabetes mellitus

Article Title: Reply to “Clarifying COMISA in diabetes: distinguishing true insomnia comorbidity from OSA-related sleep disruption”

Article References: Peker, Y., Gürkan, C. G., & on behalf of the TURKAPNE Study Group (2026). Reply to “Clarifying COMISA in diabetes: distinguishing true insomnia comorbidity from OSA-related sleep disruption”. Journal of Clinical Sleep Medicine, 22(1), Article 141. https://doi.org/10.1007/s44470-026-00158-9

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00158-9

Keywords: COMISA, insomnia, obstructive sleep apnea, diabetes mellitus, type 2 diabetes, sleep medicine, TURKAPNE cohort, sleep fragmentation, CPAP therapy, cognitive behavioral therapy, sleep disorders, diagnostics

The scientific backdrop is sobering. According to United Nations figures cited by the authors, roughly 800 million people worldwide were aged 65 or older in 2023, and the global elderly population is projected to surpass one billion during the 2030s. In China alone, 310 million people, about 22 percent of the population, are now aged 60 or over. Aging brings a cascade of tissue decline: sarcopenia, insomnia, coronary heart disease, and other conditions that erode quality of life and burden health systems. Disrupted circadian rhythms are among the earliest signals of aging in both humans and flies, appearing as phase advances and sleep fragmentation. Yet while the brain’s circadian circuitry has been studied extensively, the role of clock genes inside skeletal muscle during aging remained largely unexplored, a gap the new study set out to fill.

Tim occupies a distinctive position in biology because it is highly conserved from flies to humans and performs two jobs at once. In Drosophila, the molecular clock runs on a feedback loop: the CLK/CYC protein complex switches on transcription of the Per and Tim genes, whose protein products accumulate in the cytoplasm, shuttle into the nucleus, and shut their own genes down again until degradation resets the cycle. Light rapidly degrades TIM, allowing the clock to track the day-night cycle. In mammals, the Tim homolog has shifted evolutionarily toward cell-cycle control and genome maintenance; when DNA damage or replication stress strikes, TIM stabilizes replication forks and, together with the protein Tipin, helps activate the S-phase checkpoint, pausing the cell cycle long enough for repair. TIM also indirectly shapes metabolism, influencing glucose handling and energy balance through the clock’s downstream gene networks. What happens to these functions in aging muscle, however, was unknown.

To answer that question, the team exploited the genetic precision available in Drosophila. Using the Gal4/UAS system, they crossed flies carrying a Tim overexpression construct or a Tim RNA interference construct with flies carrying Mhc-Gal4, a driver that acts specifically in muscle. The resulting male offspring overexpressed, underexpressed, or normally expressed Tim exclusively in their muscles. Exercise was imposed with a rotating power tower apparatus: vials spun at 60 radians per second forced flies to repeatedly climb, with structured sessions totaling roughly an hour of activity per day, following a two-days-on, one-day-off rhythm for four weeks starting at two weeks of age. The researchers then measured 24-hour locomotor activity from video, climbing speed, heart rate and stroke volume captured by high-speed video of surgically exposed beating hearts, time to cardiac arrest under artificial hemolymph, and lifespan across groups of roughly 200 flies each.

The results from genetic suppression were striking. In one-week-old young flies, knocking down muscle Tim changed nothing measurable: activity, climbing speed, heart rate, stroke volume, and hypoxic cardiac failure time all remained normal. But by five weeks of age, the RNAi flies began falling apart. Their nighttime activity rose significantly, a signature of fragmented sleep, while climbing speed dropped, heart rate climbed, stroke volume shrank, hearts failed faster under hypoxia, and lifespan shortened. Aging itself pushed normal flies in the same direction, increasing nighttime activity and stressing the heart, but the Tim knockdown made everything worse. The overexpression experiment provided the mirror image: in aged flies, extra muscle Tim significantly reduced nighttime restlessness, boosted climbing speed, lowered heart rate, improved stroke volume, extended time to hypoxic heart failure, and lengthened lifespan, with no effect whatsoever in young flies. Tim, in other words, appears to govern how muscle ages, not how it develops or functions in youth.

Zooming into the muscle itself revealed the mechanism. Quantitative PCR and biochemical assays showed that Tim knockdown suppressed the expression of Clk, Sir2, and PGC-1alpha, reduced the mitochondrial respiratory chain complex I protein MRCC-I, decreased the expression of the contractile protein gene Mhc and its protein product, and lowered the activity of the antioxidant enzyme superoxide dismutase, all while reactive oxygen species accumulated. Transmission electron microscopy confirmed the damage visually: fewer mitochondria and frayed, disorganized myofibrils. Tim overexpression produced the opposite profile, upregulating the entire pathway, raising MRCC-I and SOD activity, cutting ROS, increasing mitochondrial abundance, and restoring myofibril integrity. The authors interpret this as a Timeless/Clock pathway working in parallel with a Timeless/Sir2/PGC-1alpha axis, with Sir2, the fly equivalent of the NAD+-dependent deacetylase SIRT1, promoting mitochondrial biogenesis and antioxidant defense through PGC-1alpha, a master regulator of energy metabolism.

The Sir2 connection carries real weight in aging biology. SIRT1 and related sirtuins protect heart and skeletal muscle by deacetylating and activating PGC-1alpha, which drives expression of mitochondrial assembly factors such as NRF1 and TFAM, and by activating the FOXO pathway to induce antioxidant enzymes like SOD2 and catalase. Aging depletes sirtuin levels in mammals, and SIRT1-deficient young mouse hearts show aging-like vulnerability to ischemia-reperfusion injury. What the fly study adds is the link upstream: for the first time, muscle Tim is shown to activate the Sir2/PGC-1alpha/MRCC-I pathway, positioning the circadian protein as a trigger for the mitochondrial machinery that keeps muscle and heart cells youthful.

Then comes the exercise twist. When the researchers subjected Tim knockdown flies, normal flies, and Tim overexpression flies to the four-week climbing regimen, exercise improved outcomes across all genetic backgrounds. Trained aged flies climbed faster, showed reduced overall and nighttime activity indicating better-consolidated sleep, had slower and stronger heartbeats with improved stroke volume, resisted hypoxic heart failure longer, and lived longer. Molecularly, exercise raised mRNA levels of Tim, Clk, Sir2, PGC-1alpha, and Mhc, elevated MRCC-I protein, increased mitochondrial number while reducing mitochondrial damage, boosted SOD activity, and lowered ROS. Critically, exercise upregulated Tim even in flies whose muscles were engineered for knockdown or overexpression, which positions exercise as an upstream regulator of the muscle Timeless gene rather than a bypass around it. The exercise program, in effect, retuned the same molecular circuit the genetic experiments had identified.

These findings dovetail with a broad literature showing that regular aerobic exercise ameliorates age-related sleep disturbances, preserves muscle mass, and reduces cardiovascular disease incidence, benefits that appear conserved from humans to flies. The molecular logic is also consistent: exercise raises NAD+ levels, enhancing Sirt1/Sir2 activity, which activates PGC-1alpha and FOXO to promote mitochondrial biogenesis and antioxidant capacity in muscle and heart. The new study welds these threads together by placing Tim above the sirtuin axis and showing that exercise pulls the same lever. Still, the authors are careful about limits. The Drosophila model diverges from mammalian biology; the mechanical rotation paradigm differs from voluntary human exercise; molecular measurements were confined largely to mRNA and protein levels without direct NAD+/NADH quantification or tissue-specific rescue experiments; only male flies were studied, leaving sex differences unexplored; and the precise upstream signal by which exercise, whether mechanical, metabolic, or redox-sensitive, elevates Tim expression remains unknown.

Even with those caveats, the implications are compelling. The work reframes skeletal muscle not merely as an engine of movement but as an endocrine and circadian organ whose internal clock helps time the aging of the whole organism, including the heart. If a conserved clock gene in muscle mediates exercise’s systemic benefits, future interventions might target the Timeless/Sir2/PGC-1alpha axis directly, whether through drugs that boost NAD+-dependent sirtuin activity, molecules that stabilize TIM, or exercise prescriptions optimized to stimulate the pathway. For now, the humble fruit fly has delivered a message that resonates far beyond the vial: when aging frays the body’s rhythms and weakens its heart, moving the muscles may reset the molecular clock that keeps both running.

Subject of Research: Muscle-specific Timeless gene regulation of exercise-induced protection against circadian, muscular, and cardiac aging in Drosophila

Article Title: Muscle‐Specific Upregulation of Timeless Mediates Exercise‐Induced Amelioration of Age‐Related Circadian Rhythm Disruption and Cardiac Dysfunction in Drosophila

Article References: Wen, D.-T., Lv, S., Sun, J.-Y., Chen, Y.-Q., Lin, Y., Du, Z.-R., Sun, G.-B., Yuan, T.-S., Shu, D., & Hou, W.-Q. (2026). Muscle‐Specific Upregulation of Timeless Mediates Exercise‐Induced Amelioration of Age‐Related Circadian Rhythm Disruption and Cardiac Dysfunction in Drosophila. Aging Cell, 25(9), Article e70708. https://doi.org/10.1111/acel.70708

Image Credits: AI Generated

DOI: 10.1111/acel.70708

Keywords: Timeless gene, circadian rhythm, exercise, aging, Drosophila, skeletal muscle, cardiac dysfunction, Sir2, PGC-1alpha, mitochondria, oxidative stress, sleep fragmentation

The letter, authored by Bin Huang of the Department of Rehabilitation Medicine and Yuqian Shen of the Traditional Chinese Medicine Department at Suzhou Ninth People’s Hospital in Suzhou, China, takes aim at the growing practice of interpreting slow-wave slope measurements in patients with obstructive sleep apnea as direct markers of synaptic homeostasis. Writing in response to a recent population-based cohort study that reported sleep homeostasis impairment across the severity spectrum of obstructive sleep apnea, Huang and Shen do not dispute the clinical importance of the findings. Instead, they raise a methodological concern with potentially wide consequences: the electrophysiological signal that researchers are reading as a gauge of synaptic strength is entangled with multiple brain-altering processes in sleep apnea that have nothing to do with synaptic downscaling, and may therefore distort the measurement in ways that are difficult to disentangle.

The theoretical appeal of the slow-wave slope is easy to understand. Grounded in the synaptic homeostasis framework developed by Giulio Tononi and Chiara Cirelli, the reasoning holds that waking life potentiates synapses across the cortex, increasing the energetic cost of neural activity and saturating the capacity for further learning. Sleep, particularly slow-wave sleep, is proposed to renormalize this synaptic burden. High-density electroencephalography studies in humans, including the landmark work of Riedner and colleagues, demonstrated that the slope and amplitude of individual slow waves decline systematically across a night of sleep, tracking the dissipation of homeostatic sleep pressure. Because slope is less sensitive than amplitude to volume conduction and reference-electrode artifacts, many investigators consider it the cleaner measure of the underlying cortical synchronization, and by extension, of the synaptic substrate that generates it.

Obstructive sleep apnea, however, is not a neutral backdrop against which this synaptic story unfolds. The disorder imposes a cascade of stressors on the cortex that are capable of changing slow-wave morphology in their own right. Chronic intermittent hypoxia, repeated arousals that shatter the continuity of slow-wave sleep, blood pressure surges, carbon dioxide fluctuations, and systemic inflammation all accompany the apneic night. Beyond these acute disturbances, imaging work by Macey, Kumar, Harper and colleagues has documented structural changes in the brains of patients with obstructive sleep apnea, including alterations in gray matter volume in regions responsible for generating and propagating slow oscillations. If the cortical tissue itself has been reshaped by years of nocturnal suffocation, Huang and Shen argue, then any observed flattening of slow-wave slope in these patients could reflect neuronal loss, cortical thinning, or impaired network connectivity rather than a genuine deficit in the synaptic downscaling process that homeostatic theory describes.

This distinction matters because the two explanations lead to different conclusions about what is broken in the apneic brain. A flattened slow-wave slope interpreted as impaired synaptic homeostasis suggests that the fundamental sleep-dependent mechanism of synaptic renormalization is failing, with downstream consequences for memory consolidation, synaptic pruning, and cognitive resilience. The same measurement interpreted as a byproduct of structural brain injury or hypoxia-related neuronal dysfunction points instead toward damage that may or may not respond to restoring normal sleep architecture with continuous positive airway pressure therapy. Treatment studies that use slow-wave slope as an outcome measure would, in the second scenario, risk drawing misleading inferences about whether therapy has revived a dormant homeostatic process when the slope change might instead track the partial recovery of injured cortical networks or the resolution of hypoxic stress.

The letter also highlights problems that arise even before the brain’s pathophysiology enters the picture. Slow-wave detection and slope quantification are sensitive to the algorithms used, the electroencephalographic derivations examined, the thresholds for event detection, and the manner in which artifacts from respiration, movement, and arousal are handled. Patients with obstructive sleep apnea generate unusually noisy sleep recordings: respiratory artifacts contaminate the signal, arousals fragment epochs, and stage shifts compress the amount of analyzable slow-wave sleep. Population-based studies, which are invaluable for capturing the full severity spectrum of the disorder, often rely on limited electroencephalographic montages that may not sample the cortical regions where slow waves originate or where apnea-related damage concentrates. Slope estimates drawn from a small number of derivations may therefore not generalize to the whole-cortex synchronization dynamics that the homeostatic framework actually describes.

Compounding these technical issues is the question of what the slope is being compared against. The canonical decline of slow-wave slope across the night was established in healthy, typically young adults sleeping undisturbed. In a patient whose slow-wave sleep is repeatedly interrupted, the expected trajectory of homeostatic dissipation may be altered simply because sleep pressure dynamics themselves are disrupted by fragmentation, independent of any change in synaptic machinery. A lower slope at a given point in the night could indicate faster dissipation, impaired build-up of sleep pressure during the preceding wake period, or a cortex that synchronizes differently because its cells and connections have been remodeled by chronic disease. Without careful controls for apnea severity, oxygen desaturation burden, arousal frequency, age, and comorbid conditions, the letter contends, attributing slope differences specifically to synaptic homeostasis overreaches what the data can support.

None of this means that slow-wave slope should be abandoned as an investigative tool. Huang and Shen are careful to frame their argument as a call for methodological caution rather than a rejection of the measure. Slow-wave slope remains one of the most informative electrophysiological indices available in human sleep research, and the population-based evidence that sleep homeostasis is altered in obstructive sleep apnea is clinically significant in its own right, independent of the synaptic interpretation attached to it. The authors’ concern is that the field is at risk of building an explanatory edifice on a signal whose meaning in this patient population is confounded at multiple levels. The remedy they imply is methodological pluralism: combining slope measurements with complementary approaches such as high-density EEG mapping, measures of sleep pressure built from slow-wave activity, neuroimaging of cortical structure, and longitudinal designs that track patients before and after effective treatment of their breathing disorder.

For clinicians and researchers following the rapidly expanding literature on sleep apnea and brain health, the message is a sobering one. Obstructive sleep apnea affects hundreds of millions of people worldwide and is increasingly linked to cognitive decline, dementia risk, and impaired emotional regulation. Slow-wave sleep sits at the center of many proposed mechanisms connecting the disorder to these outcomes, and slow-wave slope has become a shorthand for the health of the sleeping brain. The letter from Suzhou reminds the field that a shorthand is not a mechanism. Until the confounding contributions of hypoxia, fragmentation, cortical structural change, and measurement methodology are systematically separated, the slope of a slow wave in a patient with sleep apnea should be read as an intriguing and imperfect signal, not as a direct readout of synaptic homeostasis. The nightly downscaling of synapses may well be impaired in obstructive sleep apnea—but proving it will require more than reading the steepness of the brain’s deepest waves.

Subject of Research: Methodological limitations of using EEG slow-wave slope as a marker of synaptic homeostasis in obstructive sleep apnea

Article Title: Methodological caveats in interpreting slow-wave slope as a marker of synaptic homeostasis in OSA

Article References: Huang, B., & Shen, Y. (2026). Methodological caveats in interpreting slow-wave slope as a marker of synaptic homeostasis in OSA. Journal of Clinical Sleep Medicine, 22(1), Article 168. https://doi.org/10.1007/s44470-026-00189-2

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00189-2

Keywords: obstructive sleep apnea, slow-wave slope, synaptic homeostasis hypothesis, slow-wave sleep, EEG, sleep homeostasis, intermittent hypoxia, synaptic downscaling, sleep fragmentation, cortical structure, neurophysiology, sleep medicine